Price History
Feb 9, 2026 — Apr 4, 2026Investment Snapshot
- Trading 203% above Graham Number — above intrinsic value estimate
- Piotroski F-Score 3/9 — signs of financial weakness
- ROE of 44.1% — good return on equity
Advanced Biomed Inc. (ADVB) is a Healthcare company operating in Services-Medical Laboratories, listed on the NASDAQ , with a market capitalisation of $90 million . Key value metrics: P/E ratio 21.6, P/B ratio 9.54, Piotroski F-Score 3 out of 9 .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 2 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Advanced Biomed Inc. — Fundamental Analysis Summary
Advanced Biomed Inc. (ADVB) is currently trading 203% above its Graham Number of $1.38, suggesting the market price exceeds Benjamin Graham's intrinsic value estimate. The stock carries an elevated trailing P/E ratio of 21.6x.
On financial health, ADVB shows a weak Piotroski F-Score of 3/9, a signal of deteriorating financial health, and strong return on equity of 44.1% (sector average: -19.8%), and minimal leverage with a debt-to-equity ratio of 0.14.
StockPik's composite Value Score for ADVB is 45/100 — reflecting current market or financial concerns. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
ADVB shows earnings declining at 17%.